Market research
BWAY Brainsway Ltd
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 592M
- P/E ratio
- 64.09
- Analyst target
- 18.6
- Dividend yield
- Not available
- Beta
- 0.1
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Medical Devices
- ISIN
- US10501L1061
- Market cap
- 592M
- P/E ratio
- 64.09
- Analyst target
- 18.6
- Dividend yield
- Not available
- Beta
- 0.1
About
About Brainsway Ltd
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious and late-life depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post-traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. The company was founded in 2003 and is headquartered in Jerusalem, Israel.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the BWAY discussion.
5 years, 4 months ago
Brainsway Ltd is currently in a long term uptrend where the price is trading 18.5% above its 200 day moving average.
From a valuation standpoint, the stock is 99.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 4.8.
Brainsway Ltd's total revenue rose by 12.3% to $7M since the same quarter in the previous year.
Its net income has increased by 82.5% to $-406K since the same quarter in the previous year.
Finally, its free cash flow grew by 28.9% to $-1M since the same quarter in the previous year.
Based on the above factors, Brainsway Ltd gets an overall score of 5/5.